Literature DB >> 11013180

Long-term follow-up of trabeculectomy with intraoperative 5-fluorouracil for uveitis-related glaucoma.

H M Towler1, P McCluskey, B Shaer, S Lightman.   

Abstract

PURPOSE: To determine the effect of intraoperative application of 5-fluorouracil (5-FU) on the long-term outcome of trabeculectomy in uveitis-related glaucoma.
DESIGN: An open, prospective, noncomparative case study to evaluate the use of intraoperative application for 5 minutes of 25 mg/ml 5-FU in primary trabeculectomy for uveitis-related glaucoma. PARTICIPANTS: Fifty eyes of 43 consecutive patients were enrolled in the study.
METHODS: Data were recorded prospectively on specifically designed forms at visits every 3 months after surgery. MAIN OUTCOME MEASURES: The intraocular pressure, need for additional medication, and the need for repeat surgery were the criteria that determined the outcome of surgery.
RESULTS: No significant intraoperative, postoperative, or late complications of 5-FU administration were noted. Successful filtration was achieved in 82% of eyes at 1 and 2 years after surgery. The success rate was 67% at 5 years. Failure was significantly more common and occurred earlier in patients of black ethnic origin. No deleterious effect on control of uveitis in relation to surgical intervention was observed.
CONCLUSIONS: Intraoperative application of 5-FU appears to be a long-term, safe, and effective adjunct to trabeculectomy in uveitis-related glaucoma.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11013180     DOI: 10.1016/s0161-6420(00)00351-1

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  20 in total

1.  Long-term reduction of laser flare values after trabeculectomy but not after cyclodestructive procedures in uveitis patients.

Authors:  Carsten Heinz; Beatrix Zurek-Imhoff; Jörg Koch; Martin Rösel; Arnd Heiligenhaus
Journal:  Int Ophthalmol       Date:  2011-03-25       Impact factor: 2.031

2.  Dose, timing and frequency of subconjunctival 5-fluorouracil injections after glaucoma filtering surgery.

Authors:  Eva Kristina Reinthal; Paul Oliver Denk; Matthias Grüb; Dorothea Besch; Karl Ulrich Bartz-Schmidt
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-10-17       Impact factor: 3.117

3.  Surgical outcomes of inflammatory glaucoma: a comparison of trabeculectomy and glaucoma-drainage-device implantation.

Authors:  Shawn M Iverson; Namita Bhardwaj; Wei Shi; Mitra Sehi; David S Greenfield; Donald L Budenz; Krishna Kishor
Journal:  Jpn J Ophthalmol       Date:  2015-02-17       Impact factor: 2.447

4.  [Secondary glaucoma in uveitis].

Authors:  C M E Deuter; T Klinik; M Müller; G Geerling; M Zierhut
Journal:  Ophthalmologe       Date:  2010-05       Impact factor: 1.059

5.  Trabeculectomy ab interno with the Trabectome® as a therapeutic option for uveitic secondary glaucoma.

Authors:  Alexandra Anton; Sonja Heinzelmann; Thomas Neß; Jan Lübke; Matthias Neuburger; Jens F Jordan; Thomas Wecker
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-07-24       Impact factor: 3.117

6.  Deep sclerectomy for uveitic glaucoma: long-term outcomes.

Authors:  K Mercieca; L Steeples; N Anand
Journal:  Eye (Lond)       Date:  2017-06-23       Impact factor: 3.775

7.  Efficacy and safety of deep sclerectomy in uveitic glaucoma.

Authors:  Saleh A Al Obeidan; Essam A Osman; Abdulrahman M Al-Muammar; Ahmed M Abu El-Asrar
Journal:  Int Ophthalmol       Date:  2008-06-19       Impact factor: 2.031

Review 8.  [Intraocular pressure related to uveitis].

Authors:  U Pleyer; P Ruokonen; C Heinz; A Heiligenhaus
Journal:  Ophthalmologe       Date:  2008-05       Impact factor: 1.059

Review 9.  [Glaucoma and uveitis. Causes of and treatment options for increased intraocular pressure in cases of inflammatory ophthalmology].

Authors:  T S Dietlein
Journal:  Ophthalmologe       Date:  2003-11       Impact factor: 1.059

10.  Surgical management of secondary glaucoma in Fuchs' heterochromic iridocyclitis.

Authors:  Yi-An You; Yaming Wu; Saijing Hu
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-03-22       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.